Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC).

F O MildnerM M SykoraH HacklA AmannB ZelgerS SprungM L BuchF NoceraP MoserH MaierF AugustinC ManzlF KocherA PircherJ LindenmannI MykoliukS RaftopoulouJ KarglD WolfS SopperG Gamerith

Published in: Lung cancer (Amsterdam, Netherlands) (2024)

Although in vitro and TCGA data support the suppressive effect of sPD-L1 we were unable to translate this in our clinical setting. These results may be due to the small patient number and their heterogeneity as well as the lack of a standardized sPD-L1 ELISA. Our inconclusive results regarding the value of sPD-L1 in early stage NSCLC warrant assay validation and further investigation in larger (neo-)adjuvant trials.

Keyphrases

early stage
small cell lung cancer
advanced non small cell lung cancer
free survival
sentinel lymph node
electronic health record
case report
high throughput
single cell
deep learning
monoclonal antibody
neoadjuvant chemotherapy
artificial intelligence